There is other options for financing through the different phases without dilutive Cap raises.
Big Pharma partnering and or cornerstone investment is likely on FDA approval IMO.
Some dilution is likely going forward but to use an extra 1.3billion shares in your calculations is flawed logic IMO.
Ann: Half Yearly Report and Accounts, page-9
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.796M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12500 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 27998 | 1 |
View Market Depth
| Last trade - 16.12pm 07/06/2024 (20 minute delay) ? |
| NSB (ASX) Chart |
Day chart unavailable